Suppr超能文献

因子 V 东得克萨斯变异导致三代家系出血。

Factor V east Texas variant causes bleeding in a three-generation family.

机构信息

Versiti Blood Research Institute, Milwaukee, Wisconsin, USA.

Indiana Hemophilia & Thrombosis Center, Indianapolis, Indiana, USA.

出版信息

J Thromb Haemost. 2022 Mar;20(3):565-573. doi: 10.1111/jth.15612. Epub 2021 Dec 7.

Abstract

BACKGROUND

The factor V east Texas bleeding disorder (FVETBD) is caused by increased plasma tissue factor pathway inhibitor-α (TFPIα) concentration. The underlying cause is a variant in F5 causing alternative splicing within exon 13 and producing FV-short, which tightly binds the C-terminus of TFPIα, prolonging its circulatory half-life.

OBJECTIVES

To diagnose a family presenting with variable bleeding and laboratory phenotypes.

PATIENTS/METHODS: Samples were obtained from 17 family members for F5 exon 13 sequencing. Plasma/platelet TFPI and platelet FV were measured by ELISA and/or western blot. Plasma thrombin generation potential was evaluated using calibrated automated thrombography.

RESULTS

The FVET variant was identified in all family members with bleeding symptoms and associated with elevated plasma TFPIα (4.5- to 13.4-fold) and total TFPI (2- to 3-fold). However, TFPIα and FV-short were not elevated in platelets. TF-initiated thrombin generation in patient plasma was diminished but was restored by a monoclonal anti-TFPI antibody or factor VIIa. TFPIα localized within vascular extracellular matrix in an oral lesion biopsy from an affected family member.

CONCLUSIONS

Factor V east Texas bleeding disorder was diagnosed in an extended family. The variant was autosomal dominant and highly penetrant. Elevated plasma TFPIα, rather than platelet TFPIα, was likely the primary cause of bleeding. Plasma FV-short did not deplete TFPIα from extracellular matrix. In vitro thrombin generation was restored with an anti-TFPI antibody or factor VIIa suggesting effective therapies may be available. Increased awareness of, and testing for, bleeding disorders associated with F5 exon 13 variants and elevated plasma TFPI are needed.

摘要

背景

因子 V 东得克萨斯州出血障碍(FVETBD)是由血浆组织因子途径抑制剂-α(TFPIα)浓度升高引起的。其根本原因是 F5 中的变体导致内含子 13 中的选择性剪接,并产生 FV-short,其紧密结合 TFPIα 的 C 末端,延长其循环半衰期。

目的

诊断一个具有不同出血和实验室表型的家族。

患者/方法:从 17 名家族成员中获取 F5 外显子 13 测序样本。通过 ELISA 和/或 Western blot 测量血浆/血小板 TFPI 和血小板 FV。使用校准自动血栓生成术评估血浆凝血酶生成潜力。

结果

在所有有出血症状的家族成员中均发现了 FVET 变体,与血浆 TFPIα(4.5-13.4 倍)和总 TFPI(2-3 倍)升高有关。然而,血小板中 TFPIα 和 FV-short 没有升高。患者血浆中 TF 引发的凝血酶生成减少,但通过单克隆抗 TFPI 抗体或因子 VIIa 恢复。TFPIα 定位于受影响家族成员口腔病变活检中的血管细胞外基质中。

结论

在一个大家庭中诊断出因子 V 东得克萨斯州出血障碍。该变体是常染色体显性遗传且高度外显。升高的血浆 TFPIα,而不是血小板 TFPIα,可能是出血的主要原因。血浆 FV-short 并未从细胞外基质中耗尽 TFPIα。体外凝血酶生成用抗 TFPI 抗体或因子 VIIa 恢复,表明可能有有效的治疗方法。需要提高对与 F5 外显子 13 变体和升高的血浆 TFPI 相关的出血性疾病的认识和检测。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/524e/8885967/eb8164451c8b/nihms-1760544-f0001.jpg

相似文献

引用本文的文献

4
Factor V variants in bleeding and thrombosis.出血和血栓形成中的凝血因子V变体
Res Pract Thromb Haemost. 2024 Jan 26;8(1):102330. doi: 10.1016/j.rpth.2024.102330. eCollection 2024 Jan.

本文引用的文献

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验